For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Selling, general and administrative | 1,027,179 | - | 990,737 | 1,800,778 |
| Total operating expenses | 1,027,179 | - | 990,737 | 1,800,778 |
| Loss from continuing operations | -1,027,179 | - | -990,737 | -1,800,778 |
| Change in fair value of warrant liability | - | - | -1,000 | 329,343 |
| Interest income | 40,143 | - | 67,014 | 88,849 |
| Total other income, net | 40,143 | - | 68,014 | -240,494 |
| Loss before income taxes | -987,036 | - | -922,723 | -2,041,272 |
| Loss from continuing operations, net of tax | -987,036 | -54,049.5* | -922,723 | -2,041,272 |
| Gain (loss) from discontinued operations | - | - | - | 500,816 |
| Gain from assignment of subsidiaries and vivus settlement | - | - | - | 6,973,302 |
| Net loss | -987,036 | - | -922,723 | 5,432,846 |
| Preferred stock dividends, income statement impact | - | 56,467,170* | 231,210 | - |
| Preferred stock, accretion of redemption discount | - | 0* | - | - |
| Net income (loss) from continuing operations available to common shareholders, basic | - | -56,521,219.5 | -1,153,933 | - |
| Basic EPS | -0.03 | -2.014 | -0.03 | -1.29 |
| Diluted EPS | -0.03 | -2.014 | -0.03 | -1.29 |
| Basic Average Shares | 46,222,502 | 28,065,362* | 42,284,502 | 25,922,503 |
| Diluted Average Shares | 46,222,502 | 28,065,362* | 42,284,502 | 25,922,503 |
Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)